Literature DB >> 35091420

Regulatory decisions diverge over aducanumab for Alzheimer's disease.

Mark P Lythgoe, Kristina Jenei, Vinay Prasad.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35091420     DOI: 10.1136/bmj-2021-069780

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  1 in total

Review 1.  Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.

Authors:  Miguel Vaz; Vítor Silva; Cristina Monteiro; Samuel Silvestre
Journal:  Clin Interv Aging       Date:  2022-05-18       Impact factor: 3.829

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.